Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Breast Neoplasms 3Recurrence 2Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Carcinoma, Non-Small-Cell Lung 2Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Hodgkin Disease 1Glioblastoma 1Eye Neoplasms 1Carcinoma, Transitional Cell 1Adenocarcinoma 1

Interventions

Cyclophosphamide 26fludarabine 16Etoposide 15Melphalan 13romidepsin 12Gemcitabine 11Whole-Body Irradiation 10Vincristine 10Peripheral Blood Stem Cell Transplantation 10Doxorubicin 10fludarabine phosphate 9Rituximab 9Lenalidomide 9Cytarabine 9Busulfan 9pembrolizumab 8Prednisone 8Mycophenolic Acid 8Granulocyte Colony-Stimulating Factor 8Bortezomib 8Filgrastim 7Carmustine 7Brentuximab Vedotin 7Biopsy 7duvelisib 6Tacrolimus 6Specimen Handling 6Dexamethasone 6Bendamustine Hydrochloride 6ruxolitinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, T-Cell × belinostat × Clear all
NCT02875002 2017-12-22

Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas

Yale University

Phase 1 Withdrawn
Lymphoid

Lymphoma, Recurrence, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡